CTLA4 and cancer: Recently, immune checkpoint inhibitors (ICIs) and monoclonal antibodies against immune checkpoint molecules, such as anti-CTLA-4, anti-PD-1 and anti-PD-L1, have been studied in various types of cancers, and these agents are routinely used in the clinic (11, 12).